Colon Cancer News and Research

Latest Colon Cancer News and Research

HTG, JWCI collaborate to develop new approaches for early stage primary cutaneous melanoma diagnosis

HTG, Inc., provider of the quantitative Nuclease Protection Assay (qNPA™), today announced it signed a collaboration agreement with the John Wayne Cancer Institute (JWCI) at Saint John's Health Center in Santa Monica, California. Under the terms of the agreement, HTG and JWCI (Department of Molecular Oncology, Dave S. B. Hoon, Ph.D., Director) will collaborate to generate a novel mRNA signature that can measure the gene expression differences in melanoma and benign nevi using HTG's qNPA technology in classical surgical pathology samples.

3 May 2010

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

Ethicon Endo-Surgery today announced that the SEDASYS® System, the first computer-assisted personalized sedation (CAPS) system, was granted a CE Mark for the European Union for routine colonoscopy and screening of the upper gastrointestinal tract (EGD procedures), and Health Canada granted regulatory approval for the SEDASYS® System for use by healthcare professional teams during routine colonoscopy.

3 May 2010

Study indicates older women with diabetes have increase risk for colon cancer

A research team led by Mayo Clinic physicians has found that older women with diabetes face a more than doubled risk for some types of colorectal cancer.

3 May 2010

Researchers find better way to prep patients for colonoscopy procedures

Researchers at Henry Ford Hospital may have found a better way to prep patients for colonoscopy procedures so they no longer need to drink a gallon of prescribed fluids prior to the procedure.

3 May 2010

Research shows microRNA can silence genes that protect genome from cancer-causing mutations

New research shows for the first time that molecules called microRNA can silence genes that protect the genome from cancer-causing mutations.

30 Apr 2010

CRH Medical reports 115% increase in first-quarter 2010 revenue

CRH Medical Corporation announced today unaudited results for the three months ended March 31, 2010. Total revenue for the three months ended March 31, 2010 was $1,951,590 compared to $1,739,470 for the same period in 2009.

30 Apr 2010

A new approach for treating neurological and degenerative disorders

In studies on cancer, heart disease, neurological disorders and other degenerative conditions, some scientists are moving away from the "nature versus nurture" debate, and are finding you're not a creature of either genetics or environment, but both - with enormous implications for a new approach to health.

29 Apr 2010

Tumor cell factories may be difficult to defeat: Researchers

Many of the colon cancer cells that form tumors can be killed by genetically short-circuiting the cells' ability to absorb a key nutrient, a new study has found. While the findings are encouraging, the test tube study using human colon cancer cells also illustrates the difficulty of defeating these cells, known as cancer stem cells.

29 Apr 2010

Myriad Genetics OnDose collection kit eliminates need for frozen sample handling

Myriad Genetics, Inc. today announced a significant improvement in the sample collection kit for OnDoseTM, its 5-Fluorouracil (5-FU) dose optimization product. Patient sample handling can now be conducted at room temperature, eliminating the need for frozen sample handling. Myriad said that it believes the simplified process should increase physician acceptance and utilization of OnDose.

28 Apr 2010

A bitter pill to swallow

Reporting for Kaiser Health News in collaboration with The Washington Post, Sandra Boodman writes: "When Jere Carpentier learned last year that she had advanced colon cancer -- her third malignancy in a dozen years -- she worried about spending hours in a clinic tethered to an intravenous line, enduring punishing chemotherapy that would make her hair fall out.

28 Apr 2010

First Edition: April 27, 2010

Today's headlines focus on the details of health reform that continue to emerge -- including states' reactions to high risk pools and questions about the sweeping expansion of Medicaid.

27 Apr 2010

Caltech biologists offer new insight into causes of IBD and colon cancer

We are not alone-even in our own bodies. The human gut is home to 100 trillion bacteria, which, for millions of years, have co-evolved along with our digestive and immune systems. Most people view bacteria as harmful pathogens that cause infections and disease. Other, more agreeable, microbes (known as symbionts) have taken a different evolutionary path, and have established beneficial relationships with their hosts.

26 Apr 2010

Targeted therapy based on molecular signatures for treating lung cancer

The first lung cancer clinical trial to guide targeted therapies to patients based on molecular signatures in tumor biopsies is a step toward personalized care and more effective, efficient clinical trials for new drugs, study leaders reported today during the American Association for Cancer Research 101st Annual Meeting 2010.

24 Apr 2010

Patients more likely to change diet with written plan combined with counseling calls

Combining telephone counseling calls with a daily written diet plan increases a person's success in improving fruit and vegetables consumption, according to research published in Preventive Medicine.

23 Apr 2010

Research findings may help personalize use of statins, scientists say

Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered why statins -- popular drugs that lower cholesterol and appear to protect against colorectal cancer development -- work for some people, but not for all.

22 Apr 2010

Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today reported preclinical data with ASG-5ME, an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. In models of human prostate and pancreatic cancer, ASG-5ME was found to have potent and long lasting antitumor activity. The findings were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

22 Apr 2010

NO-naproxen blocks molecular changes leading to colorectal cancer development

Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.

22 Apr 2010

Study: Scientists advance toward development of urine test for detecting colon cancer

Scientists are reporting an advance toward development of a urine test for detecting colon cancer, the third most common cancer in the United States. Such a test could eventually compliment or even reduce the need for colonoscopy, the mainstay screening test used today. The study, which analyzes chemical differences in the urine of humans with and without colon cancer, is in ACS' Journal of Proteome Research, a monthly publication.

22 Apr 2010

Alchemia’s HyACT tumour targeting technology enhances killing of cancer stem cells

Alchemia's subsidiary Alchemia Oncology today presented two posters at the American Association of Cancer Research (AACR) 101st Annual Meeting in Washington, DC. The data demonstrates the ability of the Company's HyACT tumour targeting technology to dramatically enhance the killing of cancer stem cells. These cells are highly resistant to treatment with chemotherapeutic drugs and are believed to be responsible for treatment failure and disease recurrence.

21 Apr 2010

Positive preclinical pharmacokinetic data for XMT-1001 presented at AACR 2010

Mersana Therapeutics, a platform-based cancer therapeutics company, announced today positive preclinical pharmacokinetic data for its lead development candidate, XMT-1001, which is currently in a Phase 1 clinical trial in patients with advanced solid tumors. The results were presented in a poster session at the AACR 101st Annual Meeting 2010 in Washington, DC, held April 17-21, 2010.

21 Apr 2010